TrialCell reports. Medicine2025

Locoregional gemcitabine plus surufatinib and camrelizumab in FGFR2-non-altered intrahepatic cholangiocarcinoma.

Bin Guo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.